Supreme Court (SC) has issued a notice to the Centre and Ranbaxy on a PIL (Public Interest Litigation) seeking probe against the company for allegedly supplying adulterated drugs in the country. However, the SC has refused to pass an interim order to restrain the company from manufacturing drugs. This was the first time the pharma company has been penalised domestically.
If a ban is imposed on the drug, then the company is likely to lose Rs 76 crore revenue. The company is already reeling under USFDA (United States Food and Drugs Administration) imposed restrictions on all its plants. The company had last year pleaded guilty to charges related to drug safety and agreed to pay $500 million in fines under a settlement agreement with the US Department of Justice.
Ranbaxy Laboratories is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1837.15 |
| Dr. Reddys Lab | 1271.55 |
| Cipla | 1353.85 |
| Zydus Lifesciences | 1070.90 |
| Lupin | 2351.90 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: